Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections
PHASE4CompletedINTERVENTIONAL
Enrollment
314
Participants
Timeline
Start Date
October 31, 2000
Primary Completion Date
January 31, 2003
Study Completion Date
January 31, 2003
Conditions
Diabetes MellitusDiabetic Foot
Interventions
DRUG
Piperacillin/Tazobactam
All Listed Sponsors
lead
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
NCT00044746 - Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections | Biotech Hunter | Biotech Hunter